This study evaluates the role of dietary L-tryptophan, an essential amino acid, in the activation of a specific cellular component: the aryl hydrocarbon receptor.
The Aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor implicated in a range of key cellular events. In the gut, AHR is crucial for maintaining intestinal barrier immune homeostasis. The physiology of the AHR, however, is not completely understood; its precise gut luminal activators and functional consequences are unknown. Some AHR ligands originate from the diet. Commensals play crucial roles in metabolizing tryptophan and other amino acids such as tyrosine, with the subsequent production of tryptophan metabolites. Previous studies show that inflammatory bowel disease (IBD) patients have impaired production of AHR agonists by the microbiota. Furthermore, dietary supplementation with tryptophan ameliorates clinical parameters of colitis in rodent models. Whether these findings translate into human pathophysiology has not been explored. In the present study, the investigators will evaluate the effect of high- versus low-tryptophan diet on AHR activation in healthy participants. Briefly, participants will be instructed to follow a standardized low-tryptophan diet and will be randomized to a 3-week L-tryptophan supplement or placebo. Later, after a 2-week washout period, participants will crossover to the other arm. In addition, the effect of tryptophan and microbiota-derived metabolites on AHR activation will be analyzed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Enrollment
20
3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
McMaster Health Sciences Centre
Hamilton, Ontario, Canada
AHR activation levels in stool and duodenal content.
Changes in AHR activation levels will be assessed in stool and duodenal samples before and after the intervention (high- and low-tryptophan diets) using an AHR cell-reporter line.
Time frame: three weeks
Bacterial and fungal microbiota composition in stool, duodenum and rectum/sigmoid biopsies.
Changes in bacterial and fungal microbiota composition will be assessed before and after the intervention in stool samples, duodenum and rectum biopsies.
Time frame: Three weeks
Tryptophan metabolites levels, including host and bacterial catabolites, in blood, urine and stool.
Changes in tryptophan metabolites leves will be compared before and after the intervention, in blood, urine and stool samples.
Time frame: Three weeks
mRNA levels in duodenal and rectum/sigmoid biopsies.
Changes in mRNA levels in duodenal and rectum/sigmoid biopsies will be assessed before and after the intervention.
Time frame: three weeks
Cytokines in serum.
Changes in cytokines in the serum (IL-22, IL-6, IL-2, IL-10, IL-12p70, IL-23p19, IFNγ, TNFα and CRP will be measured by ELISA in cell culture supernatants after stimulation with LPS, curdlan and ConA ) will be measured before and after the intervention and patients will be grouped into two categories for each measurement: high vs. low, according to the cutoff reference test value for each of the cytokines.
Time frame: three weeks.
Gastrointestinal symptoms
Changes in gastrointestinal symptoms before and after the intervention will be assessed using a validated questionnaire (The Gastrointestinal Symptoms Rating Scale)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: three weeks.
Mood
Changes in mood before and after the intervention will be assessed using a validated questionnaire (Hospital anxiety and depression scale)
Time frame: three weeks